BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36165231)

  • 21. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression.
    Wang X; Li H; Shi J
    Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.
    Devlin JR; Hannan KM; Hein N; Cullinane C; Kusnadi E; Ng PY; George AJ; Shortt J; Bywater MJ; Poortinga G; Sanij E; Kang J; Drygin D; O'Brien S; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
    Cancer Discov; 2016 Jan; 6(1):59-70. PubMed ID: 26490423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-182-5p Promotes Growth in Oral Squamous Cell Carcinoma by Inhibiting CAMK2N1.
    Li N; Nan CC; Zhong XY; Weng JQ; Fan HD; Sun HP; Tang S; Shi L; Huang SX
    Cell Physiol Biochem; 2018; 49(4):1329-1341. PubMed ID: 30205384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. METTL3/14 and IL-17 signaling contribute to CEBPA-DT enhanced oral cancer cisplatin resistance.
    Qiao X; Zhu L; Song R; Shang C; Guo Y
    Oral Dis; 2023 Apr; 29(3):942-956. PubMed ID: 34807506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
    Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
    Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CerS6 regulates cisplatin resistance in oral squamous cell carcinoma by altering mitochondrial fission and autophagy.
    Li S; Wu Y; Ding Y; Yu M; Ai Z
    J Cell Physiol; 2018 Dec; 233(12):9416-9425. PubMed ID: 30054909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CRISPR-based kinome-screening revealed MINK1 as a druggable player to rewire 5FU-resistance in OSCC through AKT/MDM2/p53 axis.
    Mohanty S; Mohapatra P; Shriwas O; Ansari SA; Priyadarshini M; Priyadarsini S; Rath R; Sultania M; Das Majumdar SK; Swain RK; Dash R
    Oncogene; 2022 Nov; 41(45):4929-4940. PubMed ID: 36182968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VAV2 orchestrates the interplay between regenerative proliferation and ribogenesis in both keratinocytes and oral squamous cell carcinoma.
    Fernández-Parejo N; Lorenzo-Martín LF; García-Pedrero JM; Rodrigo JP; Dosil M; Bustelo XR
    Sci Rep; 2024 Feb; 14(1):4060. PubMed ID: 38374399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pluripotency transcription factor Nanog and its association with overall oral squamous cell carcinoma progression, cisplatin-resistance, invasion and stemness acquisition.
    Kashyap T; Nath N; Mishra P; Jha A; Nagini S; Mishra R
    Head Neck; 2020 Nov; 42(11):3282-3294. PubMed ID: 32710593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma.
    Chen L; Yang QC; Li YC; Yang LL; Liu JF; Li H; Xiao Y; Bu LL; Zhang WF; Sun ZJ
    Cancer Immunol Res; 2020 Feb; 8(2):179-191. PubMed ID: 31771985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated Expression of Zinc Finger Protein 703 Promotes Cell Proliferation and Metastasis through PI3K/AKT/GSK-3β Signalling in Oral Squamous Cell Carcinoma.
    Wang H; Deng X; Zhang J; Ou Z; Mai J; Ding S; Huo S
    Cell Physiol Biochem; 2017; 44(3):920-934. PubMed ID: 29176314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
    Fang L; Wang H; Zhou L; Yu D
    Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of ferroptosis by carnosic acid-mediated inactivation of Nrf2/HO-1 potentiates cisplatin responsiveness in OSCC cells.
    Han L; Li L; Wu G
    Mol Cell Probes; 2022 Aug; 64():101821. PubMed ID: 35490795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of CD168 is related to poor prognosis in oral squamous cell carcinoma.
    Zhu SW; Wang S; Wu ZZ; Yang QC; Chen DR; Wan SC; Sun ZJ
    Oral Dis; 2022 Mar; 28(2):364-372. PubMed ID: 33386685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Knocking-down of CREPT prohibits the progression of oral squamous cell carcinoma and suppresses cyclin D1 and c-Myc expression.
    Ma J; Ren Y; Zhang L; Kong X; Wang T; Shi Y; Bu R
    PLoS One; 2017; 12(4):e0174309. PubMed ID: 28369091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. c-Myc overexpression increases ribosome biogenesis and protein synthesis independent of mTORC1 activation in mouse skeletal muscle.
    Mori T; Ato S; Knudsen JR; Henriquez-Olguin C; Li Z; Wakabayashi K; Suginohara T; Higashida K; Tamura Y; Nakazato K; Jensen TE; Ogasawara R
    Am J Physiol Endocrinol Metab; 2021 Oct; 321(4):E551-E559. PubMed ID: 34423683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CircKRT1 drives tumor progression and immune evasion in oral squamous cell carcinoma by sponging miR-495-3p to regulate PDL1 expression.
    Yang Z; Chen W; Wang Y; Qin M; Ji Y
    Cell Biol Int; 2021 Jul; 45(7):1423-1435. PubMed ID: 33675276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nitrate increases cisplatin chemosensitivity of oral squamous cell carcinoma via REDD1/AKT signaling pathway.
    Feng Y; Cao X; Zhao B; Song C; Pang B; Hu L; Zhang C; Wang J; He J; Wang S
    Sci China Life Sci; 2021 Nov; 64(11):1814-1828. PubMed ID: 34542810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nucleolar HEAT Repeat Containing 1 Up-regulated by the Mechanistic Target of Rapamycin Complex 1 Signaling Promotes Hepatocellular Carcinoma Growth by Dominating Ribosome Biogenesis and Proteome Homeostasis.
    Yang XM; Wang XQ; Hu LP; Feng MX; Zhou YQ; Li DX; Li J; Miao XC; Zhang YL; Yao LL; Nie HZ; Huang S; Xia Q; Zhang XL; Jiang SH; Zhang ZG
    Gastroenterology; 2023 Sep; 165(3):629-646. PubMed ID: 37247644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p22phox confers resistance to cisplatin, by blocking its entry into the nucleus.
    Hung CC; Chien CY; Chiang WF; Lin CS; Hour TC; Chen HR; Wang LF; Ko JY; Chang CH; Chen JY
    Oncotarget; 2015 Feb; 6(6):4110-25. PubMed ID: 25686830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.